Comparative in-vitro activity of Ro 23-6240, a new trifluorinated quinolone.
The in-vitro activity of Ro 23-6240, a new quinolone, was tested in comparison with that of other quinolones against 486 recent clinical isolates. Ro 23-6240 displayed the typical features of the new quinolones: highest activity against Gram-negative bacilli, MBCs close to the MICs, minimum inoculum effect and rapid killing. Against Gram-negative organisms (Enterobacteriaceae, non-fermenters, Haemophilus influenzae and gonococci) the activity of Ro 23-6240 was between that of ofloxacin and norfloxacin; against staphylococci its activity was between that of ciprofloxacin and ofloxacin, and against streptococci it was similar to that of norfloxacin.
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D000890:Anti-Infective Agents; D002939:Ciprofloxacin / Q000031:analogs & derivatives* / Q000494:pharmacology; D015365:Enoxacin; D004755:Enterobacteriaceae / Q000187:drug effects; D016576:Fleroxacin; D024841:Fluoroquinolones; D006090:Gram-Negative Bacteria / Q000187:drug effects; D008826:Microbial Sensitivity Tests; D009287:Naphthyridines / Q000494:pharmacology; D009643:Norfloxacin / Q000494:pharmacology; D015242:Ofloxacin; D010078:Oxazines / Q000494:pharmacology
D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D024841:Fluoroquinolones; D009287:Naphthyridines; D010078:Oxazines; D015365:Enoxacin; D002939:Ciprofloxacin; C047225:difloxacin; D015242:Ofloxacin; D009643:Norfloxacin; D016576:Fleroxacin; C047224:sarafloxacin